How Gilead Sciences, Inc. Could Push Back on Sovaldi Pricing
On Tuesday's edition of Market Checkup, Motley Fool health-care analyst David Williamson looks at the biggest winners and losers in health-care stocks today.
With Gilead's miraculous new hepatitis C treatment Sovaldi boasting a 90% cure rate, but an $84,000 price tag for the 12-week treatment, several protests have been staged against the prohibitively expensive price point. Now, pharmacy benefit managers led by Express Scripts , CVS Caremark , and Catamaran are also reported to be pushing back against Sovaldi's price tag.
In this segment, David discusses the vast superiorities Gilead's drug offers over the previous treatment, and tells investors why the protestors may not have much leverage here and the price point will probably hold.
So what's the best way for investors to play the biotech space today?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article How Gilead Sciences, Inc. Could Push Back on Sovaldi Pricing originally appeared on Fool.com.
David Williamson owns shares of Express Scripts. The Motley Fool recommends Catamaran, Express Scripts, and Gilead Sciences and owns shares of Catamaran and Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.